Gene therapy for Parkinson's disease using recombinant adeno-associated viral vectors

Expert Opinion on Biological Therapy

Volumn 5, Issue 5, 2005, Pages 663-671

  Muramatsu, Shin Ichi ^a   Tsukada, Hideo ^b   Nakano, Imaharu ^a   Ozawa, Keiya ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b CENTRAL RESEARCH LABORATORY   (Japan)

Author keywords

AAV; Adeno associated virus; Dopamine; Gene therapy; Glial cell line derived neurotrophic factor; Parkinson's disease; Positron emission tomography

Indexed keywords

4 AMINOBUTYRIC ACID; DOPAMINE; DRUG CARRIER; GENE PRODUCT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PARVOVIRUS VECTOR;

BRAIN FUNCTION; CLINICAL TRIAL; CORPUS STRIATUM; DEGENERATION; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DOPAMINE METABOLISM; ENZYME LOCALIZATION; GENE DELIVERY SYSTEM; GENE EXPRESSION REGULATION; GENE THERAPY; GLIA CELL; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; INFLAMMATION; META ANALYSIS; NEUROPROTECTION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; REVIEW; SAFETY; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; SYSTEMATIC REVIEW; TRANSGENE; VIRUS PATHOGENESIS;

ADENOVIRIDAE; ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; PARKINSON DISEASE; RECOMBINANT PROTEINS;

ADENO-ASSOCIATED VIRUS; MAMMALIA;

EID: 20344396628     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.5.663     Document Type: Review

References (111)

1. HEALY DG, ABOU-SLEIMAN PM, WOOD NW: PINK, PANK, or PARK? A clinicians' guide to familial parkinsonism. Lancet Neurol. (2004) 3(11):652-662.
2. SHEN J: Protein kinases linked to the pathogenesis of Parkinson's disease. Neuron (2004) 44(4):575-577.
3. VILA M, PRZEDBORSKI S: Genetic clues to the pathogenesis of Parkinson's disease. Nat. Med. (2004) 10(Suppl.):S58-S62.
4. KISH SJ, SHANNAK K, HORNYKIEWICZ O: Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. (1988) 318(14):876-880.
5. JENNER P: Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann. Neurol. (2000) 47(4 Suppl. 1):S90-S104.
6. LANGSTON JW, QUIK M, PETZINGER G, JAKOWEC M, DI MONTE DA: Investigating levodopa-induced dyskinesias in the parkinsonian primate. Ann. Neurol. (2000) 47(4 Suppl. 1):S79-S89.
7. CAREY RJ, PINHEIRO-CARRERA M, DAI H, TOMAZ C, HUSTON JP: L-DOPA and psychosis: evidence for L-DOPA-induced increases in prefrontal cortex dopamine and in serum corticosterone. Biol. Psychiatry (1995) 38(10):669-676.
8. DU B, WU P, BOLDT-HOULE DM, TERWILLIGER EF: Efficient transduction of human neurons with an adeno-associated virus vector. Gene Ther, (1996) 3(3):254-261.
9. KAPLITT MG, LEONE P, SAMULSKI RJ et al.: Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. (1994) 8(2):148-154. First report of rAAV vector-mediated gene delivery in an animal model of PD.
10. LEFF SE, SPRATT SK, SNYDER RO, MANDEL RJ: Long-term restoration of scriatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease. Neuroscience (1999) 92(1):185-196. One of a series of reports describing DA replacement using rAAV vectors.
11. SHEN Y, MURAMATSU SI, IKEGUCHI K et al.: Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum. Gene Ther. (2000) 11(11):1509-1519. One of a series of reports describing DA replacement using rAAV vectors.
12. BERNS KI, BERGOIN M, BLOOM M et al.: Family Parvoviridae. In: Virus Taxonomy. Classification and Nomenclature of Viruses. Murphy FA (Ed.), Springer-Verlag, New York, USA (1995):169-178.
13. BANTEL-SCHAAL U, DELIUS H, SCHMIDT R, ZUR HAUSEN H: Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses. J. Virol. (1999) 73(2):939-947.
14. CHIORINI JA, KIM F, YANG L, KOTIN RM: Cloning and characterization of adeno-associated virus type 5. J. Virol. (1999) 73(2): 1309-1319.
15. CHIORINI JA, YANG L, LIU Y, SAFER B, KOTIN RM: Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. (1997) 71(9):6823-6833.
16. HANDA A, MURAMATSU S, QIU J, MIZUKAMI H, BROWN KE: Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors. J. Gen. Virol. (2000) 81(Pt 8):2077-2084.
17. MURAMATSU S, MIZUKAMI H, YOUNG NS, BROWN KE: Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. Virology (1996) 221(1):208-217.
18. RUTLEDGE EA, HALBERT CL, RUSSELL DW: Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. (1998) 72(1):309-319.
19. SRIVASTAVA A, LUSBY EW, BERNS KI: Nucleotide sequence and organization of the adeno-associated virus 2 genome. J. Virol. (1983) 45(2):555-564.
20. XIAO W, CHIRMULE N, BERTA SC et al.: Gene therapy vectors based on adeno-associated virus type 1. J. Virol. (1999) 73(5):3994-4003.
21. GAO G, VANDENBERGHE LH, ALVIRA MR et al.: Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. (2004) 78(12):6381-6388. Describes novel primate AAVs.
22. BURGER C, GORBATYUK OS, VELARDO MJ et al.: Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Ther. (2004) 10(2):302-317.
23. DAVIDSON BL, CHIORINI JA: Recombinant adeno-associated viral vector types 4 and 5. Preparation and application for CNS gene transfer. Methods Mol. Med. (2003) 76:269-285.
24. NAKAI H, FUESS S, STORM TA et al.: Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J. Virol. (2005) 79(1):214-224.
25. TENENBAUM L, CHTARTO A, LEHTONEN E et al.: Recombinant AAV-mediated gene delivery to the central nervous system. J. Gene Med. (2004) 6(Suppl. 1):S212-S222.
26. WANG C, WANG CM, CLARK KR, SFERRA TJ: Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain. Gene Ther. (2003) 10(17):1528-1534.
27. MILLER DG, RUTLEDGE EA, RUSSELL DW: Chromosomal effects of adeno-associated virus vector integration. Nat. Genet. (2002) 30(2):147-148.
28. NAKAI H, MONTINI E, FUESS S et al.: AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat. Genet. (2003) 34(3):297-302.
29. SCHNEPP BC, CLARK KR, KLEMANSKI DL, PACAK CA, JOHNSON PR: Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J. Virol. (2003) 77(6):3495-3504.
30. MCCARTY DM, YOUNG SM JR, SAMULSKI RJ: Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu. Rev. Genet. (2004) 38:819-845.
31. MONAHAN PE, JOOSS K, SANDS MS: Safety of adeno-associated virus gene therapy vectors: a current evaluation. Expert Opin. Drug Saf. (2002) 1(1):79-91. A review on the safety aspects of rAAV vectors.
32. TENENBAUM L, LEHTONEN E, MONAHAN PE: Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr. Gene Ther. (2003) 3(6):545-565. A review on the safety aspects of rAAV vectors.
33. PEDEN CS, BURGER C, MUZYCZKA N, MANDEL RJ: Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not tAAV5-mediated, gene transfer in the brain. J. Virol. (2004) 78(12):6344-6359.
34. SANFTNER LM, SUZUKI BM, DOROUDCHI MM et al.: Striatal delivery of rAAV-hAADC to tats with preexisting immunity to AAV. Mol. Ther. (2004) 9(3):403-409.
35. BANKIEWICZ KS, EBERLING JL, KOHUTNICKA M et al.: Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp. Neurol. (2000) 164(1):2-14. rAAV vector-mediated AADC gene transfer in a primate model of PD.
36. FAN DS, OGAWA M, FUJIMOTO KI et al.: Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L- amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum. Gene Ther. (1998) 9(17):2527-2535.
37. MANDEL RJ, RENDAHL KG, SPRATT SK et al.: Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinsons disease. J. Neurosci. (1998) 18(11):4271-4284. One of a series of reports describing DA replacement using rAAV vectors.
38. MURAMATSU S, FUJIMOTO K, IKEGUCHI K et al.: Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum. Gene Ther. (2002) 13(3):345-354. Demonstrates behavioural improvement in a primate model of PD.
39. SANCHEZ-PERNAUTE R, HARVEY-WHITE J, CUNNINGHAM J, BANKIEWICZ KS: Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. Mol. Ther. (2001) 4(4):324-330. One of a series of reports describing DA replacement using rAAV vectors.
40. ICHINOSE H, OHYE T, FUJITA K et al.: Quantification of mRNA of tyrosine hydroxylase and atomatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia. J. Neural Transm. Park. Dis. Dement. Sect. (1994)8(1-2):149-158.
41. KADDIS FG, CLARKSON ED, WEBER MJ et al.: Intrastriatal grafting of Cos cells stably expressing human aromatic L-amino acid decarboxylase: neurochemical effects. J. Neurochem. (1997) 68(4):1520-1526.
42. ZHONG XH, HAYCOCK JW, SHANNAK K et al.: Striatal dihydroxyphenylalanine decarboxylase and tyrosine hydroxylase protein in idiopathic Parkinson's disease and dominantly inherited olivopontocerebellar atrophy. Mov. Disord. (1995) 10(1):10-17.
43. NAKAMURA K, AHMED M, BARR E, LEIDEN JM, KANG UJ: The localization and functional contribution of striatal aromatic L-amino acid decarboxylase to L-3,4-dihydroxyphenylalanine decarboxylation in rodent parkinsonian models. Cell Transplant. (2000) 9(5):567-576.
44. TRESEDER SA, JACKSON M, JENNER P: The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates. Br. J. Pharmacol. (2000) 129(7):1355-1364.
45. NAGATSU T, ICHINOSE H: Molecular biology of catecholamine-related enzymes in relation to Parkinson's disease. Cell. Mol. Neurobiol. (1999) 19(1):57-66.
46. CORTI O, SANCHEZ-CAPELO A, COLIN P et al.: Long-term doxycycline- controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease. Proc. Natl. Acad. Sci. USA (1999) 96(21):12120-12125.
47. NAGATSU T, HORIKOSHI T, SAWADA M et al.: Biosynthesis of tetrahydrobiopterin in parkinsonian human brain. Adv. Neurol. (1987) 45:223-226.
48. ICHINOSE H, OHYE T, TAKAHASHI E et al.: Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat. Genet. (1994) 8(3):236-242.
49. HOSHIGA M, HATAKEYAMA K, WATANABE M, SHIMADA M, KAGAMIYAMA H: Autoradiographic distribution of [14C]tetrahydrobiopterin and its developmental change in mice. J. Pharmacol. Exp. Ther. (1993) 267(2):971-978.
50. DEUMENS R, BLOKLAND A, PRICKAERTS J: Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. (2002) 175(2):303-317.
51. KANG UJ, LEE WY, CHANG JW: Gene therapy for Parkinson's disease: determining the genes necessary for optimal dopamine replacement in rat models. Hum. Cell (2001) 14(1):39-48.
52. WACHTEL SR, BENCSICS C, KANG UJ: Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease. J. Neurochem. (1997) 69(5):2055-2063.
53. CARLSSON T, WINKLER C, BURGER C et al.: Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. Brain (2005) 128(Pt 3):559-569.
54. NYHOLM D, NILSSON REMAHL AI, DIZDAR N et al.: Duodenal levodopa infusion monotherapy versus oral polypharmacy in advanced Parkinson's disease. Neurology (2005) 64(2):216-223.
55. OLANOW CW, WATTS RL, KOLLER WC: An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology (2001) 56(11 Suppl. 5):S1-S88.
56. KIRIK D, GEORGIEVSKA B, BURGER C et al.: Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc. Natl. Acad. Sci. USA (2002) 99(7):4708-4713. One of a series of reports describing GDNF gene transfer using rAAV vectors in a rat model of PD.
57. HURELBRINK CB, BARKER RA: The potential of GDNF as a treatment for Parkinson's disease. Exp. Neurol. (2004) 185(1):1-6.
58. MOCHIZUKI H, HAYAKAWA H, MIGITA M et al.: An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc. Natl. Acad. Sci. USA (2001) 98(19):10918-10923.
59. BOHN MC: Parkinson's disease: a neurodegenerative disease particularly amenable to gene therapy. Mol. Ther. (2000) 1(6):494-496.
60. LIN LF, DOHERTY DH, LILE JD, BEKTESH S, COLLINS F: GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science (1993) 260(5111):1130-1132.
61. KORDOWER JH, PALFI S, CHEN EY et al.: Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol. (1999) 46(3):419-424.
62. GILL SS, PATEL NK, HOTTON GR et al.: Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson's disease. Nat. Med. (2003) 9(5):589-595.
63. KIRIK D, ROSENBLAD C, BJORKLUND A, MANDEL RJ: Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci. (2000) 20(12):4686-4700.
64. MANDEL RJ, SNYDER RO, LEFF SE: Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease. Exp. Neurol. (1999) 160(1):205-214.
65. MANDEL RJ, SPRATT SK, SNYDER RO, LEFF SE: Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc. Natl. Acad. Sci. USA (1997)94(25):14083-14088.
66. MCGRATH J, LINTZ E, HOFFER BJ et al.: Adeno-associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion. Cell Transplant. (2002) 11(3):215-227.
67. WANG L, MURAMATSU S, LU Y et al.: Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther. (2002) 9(6):381-389.
68. BILANG-BLEUEL A, REVAH F, COLIN P et al.: Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson's disease. Proc. Natl. Acad. Sci. USA (1997) 94(16):8818-8823.
69. CHOI-LUNDBERG DL, LIN Q, CHANG YN et al.: Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science (1997) 275(5301):838-841.
70. CHOI-LUNDBERG DL, LIN Q, SCHALLERT T et al.: Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp. Neurol. (1998) 154(2):261-275.
71. CONNOR B, KOZLOWSKI DA, SCHALLERT T et al.: Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther. (1999) 6(12):1936-1951.
72. CONNOR B, KOZLOWSKI DA, UNNERSTALL JR et al.: Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration. Exp. Neurol. (2001) 169(1):83-95.
73. KOZLOWSKI DA, CONNOR B, TILLERSON JL, SCHALLERT T, BOHN MC: Delivery of a GDNF gene into the substantia nigra after a progressive 6- OHDA lesion maintains functional nigrostriatal connections. Exp. Neurol. (2000) 166(1):1-15.
74. AZZOUZ M, RALPH S, WONG LF et al.: Neuroprotection in a rat Parkinson model by GDNF gene therapy using EIAV vector. Neuroreport (2004) 15(6):985-990.
75. KORDOWER JH, EMBORG ME, BLOCH J et al.: Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science (2000) 290(5492):767-773. GDNF gene transfer using a lentiviral vector in a primate model of PD.
76. GRONDIN R, GASH DM: Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease. J. Neurol. (1998) 245(11 Suppl. 3):P35-P42.
77. WALTON KM: GDNF: a novel factor with therapeutic potential for neurodegenerative disorders. Mol. Neurobiol. (1999) 19(1):43-59.
78. ESLAMBOLI A, GEORGIEVSKA B, RIDLEY RM et al.: Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinsons disease. J. Neurosci. (2005) 25(4):769-777.
79. BROOKS DJ: Morphological and functional imaging studies on the diagnosis and progression of Parkinsons disease. J. Neurol. (2000) 247(Suppl. 2):II11-II18.
80. HAMANI C, SAINT-CYR JA, FRASER J, KAPLITT M, LOZANO AM: The subthalamic nucleus in the context of movement disorders. Brain (2004) 127(Pt 1):4-20.
81. LEVY R, LANG AE, DOSTROVSKY JO et al.: Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms. Brain (2001) 124(Pt 10):2105-2118.
82. WICHMANN T, KLIEM MA, DELONG MR: Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian primates. Exp. Neurol. (2001) 167(2):410-424.
83. DURING MJ, KAPLITT MG, STERN MB, EIDELBERG D: Subthalamic GAD gene transfer in Parkinson's disease patients who are candidates for deep brain stimulation. Hum. Gene Ther. (2001) 12(12):1589-1591.
84. LUO J, KAPLITT MG, FITZSIMONS HL et al.: Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science (2002) 298(5592):425-429. GAD gene transfer into the STN using rAAV vectors.
85. DOSTROVSKY J, BERGMAN H: Oscillatory activity in the basal ganglia-relationship to normal physiology and pathophysiology. Brain (2004) 127(Pt 4):721-722.
86. BROOKS DJ: PET studies on the function of dopamine in health and Parkinson's disease. Ann. NY Acad. Sci. (2003) 991:22-35. A review on PET in PD.
87. DOUDET DJ: PET studies in the MPTP model of Parkinson's disease. Adv. Neurol. (2001) 86:187-195. A review on PET in a primate model of PD.
88. RAVINA B, EIDELBERG D, AHLSKOG JE et al.: The role of radiotracer imaging in Parkinsons disease. Neurology (2005) 64(2):208-215.
89. DEJESUS OT: Positron-labeled DOPA analogs to image dopamine terminals. Drug Dev. Res. (2003) (59):249-260.
90. EBERLING JL, CUNNINGHAM J, PIVIROTTO P et al.: In vivo PET imaging of gene expression in Parkinsonian monkeys. Mol. Ther. (2003) 8(6):873-875.
91. PATE BD, KAWAMATA T, YAMADA T et al.: Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann. Neurol. (1993) 34(3):331-338.
92. SNOW BJ, TOOYAMA I, MCGEER EG et al.: Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann. Neurol. (1993) 34(3):324-330.
93. TORSTENSON R, TEDROFF J, HARTVIG P, FASTH KJ, LANGSTROM B: A comparison of 11C-labeled L-DOPA and L-fluorodopa as positron emission tomography tracers for the presynaptic dopaminergic system. J. Cereb. Blood Flow Metab. (1999) 19(10):1142-1149.
94. TSUKADA H, LINDNER KJ, HARTVIG P et al.: Effect of 6R-L-erythro-5,6,7,8- tetrahydrobiopterin and infusion of L-tyrosine on the in vivo L-[beta-11C] DOPA disposition in the monkey brain. Brain Res. (1996) 713(1-2):92-98.
95. HAYASE N, TOMIYOSHI K, WATANABE K et al.: Positron emission tomography with 4-[18F]fluoro-L-m-tyrosine in MPTP-induced hemiparkinsonian monkeys. Ann. Nucl. Med. (1995)9(3):119-123.
96. TSUKADA H, HAKADA N, NISHIYAMA S, OHBA H, KAKIUCHI T: Cholinergic neuronal modulation alters dopamine D2 receptor availability in vivo by regulating receptor affinity induced by facilitated synaptic dopamine turnover: positron emission tomography studies with microdialysis in the conscious monkey brain. J. Neurosci. (2000) 20(18):7067-7073.
97. TSUKADA H, HARADA N, NISHIYAMA S et al.: Ketamine decreased striatal [(11)C]raclopride binding with no alterations in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: multiparametric PET studies combined with microdialysis analysis. Synapse (2000) 37(2):95-103.
98. TSUKADA H, NISHIYAMA S, KAKIUCHI T et al.: Is synaptic dopamine concentration the exclusive factor which alters the in vivo binding of [11C]racloptide? PET studies combined with microdialysis in conscious monkeys. Brain Res. (1999) 841(1-2):160-169.
99. BREIER A, SU TP, SAUNDERS R et al.: Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. USA (1997) 94(6):2569-2574.
100. BROOKS DJ: Functional imaging studies on dopamine and motor control. J. Neural Transm. (2001) 108(11):1283-1298.
101. NORDSTROM JL: The antiprogestin-dependent GeneSwitch system for regulated gene therapy. Steroids (2003) 68(10-13):1085-1094.
102. RIVERA VM, GAO GP, GRANT RL et al.: Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood (2005) 105(4):1424-1430.
103. AGHA-MOHAMMADI S, O'MALLEY M, ETEMAD A et al.: Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. J. Gene Med. (2004) 6(7):817-828.
104. AHMED BY, CHAKRAVARTHY S, EGGERS R et al.: Efficient delivery of Cre-recombinase to neurons in vivo and stable transduction of neurons using adeno-associated and lentiviral vectors. BMC Neurosci. (2004) 5(1):4.
105. CAPLEN NJ: Gene therapy progress and prospects. Downregulating gene expression: the impact of RNA interference. Gene Ther. (2004) 11(16):1241-1248.
106. WADHWA R, KAUL SC, MIYAGISHI M, TAIRA K: Vectors for RNA interference. Curr. Opin. Mol. Ther. (2004) 6(4):367-372.
107. WINKLER WC, NAHVI A, ROTH A, COLLINS JA, BREAKER RR: Control of gene expression by a natural metabolite-responsive ribozyme. Nature (2004) 428(6980):281-286.
108. YEN L, SVENDSEN J, LEE JS et al.: Exogenous control of mammalian gene expression through modulation of RNA self-cleavage. Nature (2004) 431(7007):471-476.
109. MURAMATSU S, WANG L, IKEGUCHI K et al.: Adeno-associated vital vectors for Parkinsons disease. Int. Rev. Neurobiol. (2003) 55:205-222.
110. GUIGONI C, LI Q, AUBERT I et al.: Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia. J. Neurosci. (2005) 25(8):2102-2107.
111. LO BIANCO C, SCHNEIDER BL, BAUER M et al.: Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc. Natl. Acad. Sci. USA (2004) 101(50):17510-17515.